Targeted RNA‐seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes
Open Access
- 8 January 2019
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 145 (2) , 401-414
Abstract
A subset of genetic variants found through screening of patients with hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome impact RNA splicing. Through target enrichment of the transcriptome, it is possible to perform deep‐sequencing and to identify the different and even rare mRNA isoforms. A targeted RNA‐seq approach was used to analyse the naturally‐occurring splicing events for a panel of 8 breast and/or ovarian cancer susceptibility genes (BRCA1, BRCA2, RAD51C, RAD51D, PTEN, STK11, CDH1, TP53), 3 Lynch syndrome genes (MLH1, MSH2, MSH6) and the fanconi anaemia SLX4 gene, in which monoallelic mutations were found in non‐BRCA families. For BRCA1, BRCA2, RAD51C and RAD51D the results were validated by capillary electrophoresis and were compared to a non‐targeted RNA‐seq approach. We also compared splicing events from lymphoblastoid cell‐lines with those from breast and ovarian fimbriae tissues. The potential of targeted RNA‐seq to detect pathogenic changes in RNA‐splicing was validated by the inclusion of samples with previously well characterized BRCA1/2 genetic variants. In our study, we update the catalogue of normal splicing events for BRCA1/2, provide an extensive catalogue of normal RAD51C and RAD51D alternative splicing, and list splicing events found for eight other genes. Additionally, we show that our approach allowed the identification of aberrant splicing events due to the presence of BRCA1/2 genetic variants and distinguished between complete and partial splicing events. In conclusion, targeted‐RNA‐seq can be very useful to classify variants based on their putative pathogenic impact on splicing.Keywords
Funding Information
- Fundación Mutua Madrileña
- Horizon 2020 Framework Programme (BRIDGES project, 634935)
- National Health and Medical Research Council (ID1061779)
- National Breast Cancer Foundation
This publication has 51 references indexed in Scilit:
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variantsHuman Mutation, 2012
- Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genesEuropean Journal of Human Genetics, 2011
- Pathology of hereditary breast cancerCellular Oncology, 2011
- RNA sequencing: advances, challenges and opportunitiesNature Reviews Genetics, 2010
- Functional redundancy of exon 12 ofBRCA2revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variantHuman Mutation, 2009
- RNA-Seq: a revolutionary tool for transcriptomicsNature Reviews Genetics, 2009
- Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009
- Prediction and assessment of splicing alterations: implications for clinical testingHuman Mutation, 2008
- Listening to silence and understanding nonsense: exonic mutations that affect splicingNature Reviews Genetics, 2002